Results 291 to 300 of about 71,029 (345)
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The Lancet, 2021
Tyrosine-kinase inhibitors have changed the natural history of chronic myeloid leukaemia in such a way that patients with adequate access to these agents, who are properly managed, and who respond well to this treatment can expect a near-normal life expectancy.
Jorge, Cortes +2 more
openaire +3 more sources
Tyrosine-kinase inhibitors have changed the natural history of chronic myeloid leukaemia in such a way that patients with adequate access to these agents, who are properly managed, and who respond well to this treatment can expect a near-normal life expectancy.
Jorge, Cortes +2 more
openaire +3 more sources
The Lancet, 2015
Chronic myeloid leukaemia (CML) was the first leukaemia associated with a unique genetic abnormality, the Philadelphia chromosome. This results from a reciprocal translocation between chromosomes 9 and 22, which generates the BCR-ABL1 fusion gene encoding a constitutively active tyrosine kinase.
Debora A. Casolari, Junia V. Melo
openaire +4 more sources
Chronic myeloid leukaemia (CML) was the first leukaemia associated with a unique genetic abnormality, the Philadelphia chromosome. This results from a reciprocal translocation between chromosomes 9 and 22, which generates the BCR-ABL1 fusion gene encoding a constitutively active tyrosine kinase.
Debora A. Casolari, Junia V. Melo
openaire +4 more sources
The Lancet, 2007
Chronic myeloid leukaemia (CML) was the first neoplastic disease for which knowledge of the genotype led to a rationally designed therapy. As a result of its well known pathophysiology, straightforward diagnosis, well established prognostic factors, and treatment for the cause of disease, CML has been studied to an extent that far exceeds that expected
Hehlmann R +3 more
openaire +5 more sources
Chronic myeloid leukaemia (CML) was the first neoplastic disease for which knowledge of the genotype led to a rationally designed therapy. As a result of its well known pathophysiology, straightforward diagnosis, well established prognostic factors, and treatment for the cause of disease, CML has been studied to an extent that far exceeds that expected
Hehlmann R +3 more
openaire +5 more sources
Medicine, 2017
Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder resulting from a reciprocal translocation between the long arms of chromosomes 9 and 22. This is termed the Philadelphia chromosome, and leads to production of the fusion onco-protein BCR-ABL, a 210 kDa constitutively active tyrosine kinase.
Katharine Hanlon, Mhairi Copland
openaire +1 more source
Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder resulting from a reciprocal translocation between the long arms of chromosomes 9 and 22. This is termed the Philadelphia chromosome, and leads to production of the fusion onco-protein BCR-ABL, a 210 kDa constitutively active tyrosine kinase.
Katharine Hanlon, Mhairi Copland
openaire +1 more source